VISTA Emerging As New Target in Cancer Immunotherapy Say Kuick Research
Delhi, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 Report Highlights:
-
Market Potential Of VISTA Inhibitors
-
Market Commercialization Assessment Scenario
-
Partnerships, Collaborations & Agreements
-
Global VISTA Inhibitors Clinical Pipeline By Biomarker, Indication, Company, Country & Phase
-
Global VISTA Inhibitors Market Dynamics
-
Insight On 15 Companies Involved In Development Of VISTA Inhibiting Drugs
-
Role Of VISTA As Inhibitory & Costimulatory Checkpoint
Download Report: https://www.kuickresearch.com/report-vista-inhibitors-vista-immune-checkpoint-vista-antibody-clinical-trial-vista-protein
With evolution in the research and development domain and with help from technological advancements and researchers’ increasing knowledge, a number of proteins have been discovered to play central roles in development and progression of many diseases. Immune checkpoint proteins have especially come to light for their role in suppressing anti-cancer immune responses. The VISTA protein is one of the newest checkpoint proteins to be discovered which has showed potential in treating both cancer and inflammatory diseases because of its extraordinary properties that make it different from its fellow checkpoint proteins.
V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.
Though its role in inflammatory diseases has been recognized, no agonists have been reported to be under development to escalate its inhibitory actions on the immune system. Cancer is a major cause of death globally which partly explains why researchers have leaned towards its inhibitory role in cancer for drug development. This can also be attributed to the years of success immune checkpoint inhibitors have shown in the market. Besides many drugs used in the treatment of inflammatory diseases have already created a niche for themselves in the market.
The relationship between VISTA and PD-L1 is also being researched right now. With varying expression from case to case, VISTA and PD-L1 simultaneously affect the immune system and the tumor microenvironment. It has been shown that PD-1/PDL-1 inhibition still has an effect on tumors that express VISTA, but the outcome is diverse because the routes for these proteins are distinct. Following this concept, a drug candidate called CA-170 was developed under a collaboration agreement between Aurigene and Curis. CA-170 is the first drug to enter clinical trials and is also the first and the only small molecule inhibitor designed to target both VISTA and PD-L1. Both CA-170 and its precursor AUNP-12 have displayed exceptional PK-PD correlation, upping the potential of CA-170 to become the first VISTA inhibitor in the global market. The candidate has already advanced to later stages in clinical trials being held in India to check the efficacy of the drug in the treatment of stage IV lung cancer patients in combination with standard chemotherapy.